


F. No. 7-5/2016/Misc./041
Central Drugs Standard Control Organisation
Directorate General of Health Services
Ministry of Health and Family Welfare

FDA Bhawan, Kotla Road
New Delhi-110002
E-mail: dci@nic.in
Phone: 011-23236965
Fax no. 011-23236973
Dated: - 09-Nov-2016

NOTICE

Subject: Risk based inspections of the manufacturing facilities – regarding.

The officers of CDSCO (Both regulatory and laboratory) and State Drug Regulators have so far carried out inspection of 76 units manufacturing various drugs in accordance with the risk based inspection criteria evolved by the CDSCO. The reports of the inspections have been shared with the manufacturers concerned with the advice to rectify deficiencies that had been noticed during such inspections. While, no feedback has so far been received from the State Regulators about the action taken to rectify deficiencies, it is planned to carry out follow up inspections by different teams to gauge the extent of improvements made by the manufacturers. The process will begin in the month of January, 2017. The details of the programme will be sent to the individual units in due course of time. Accordingly, all units are requested to ensure that the deficiencies noticed may be removed at the earliest possible.


(Dr. G. N. Singh)
Drugs Controller General (India)